ORLANDO, Fla.--(BUSINESS WIRE)--MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, today provided a summary of the Dacogen™ (decitabine) for Injection presentations made during the American Society of Hematology (ASH) 48th Annual Meeting and Exposition. Dacogen was the subject of two oral presentations, 10 poster presentations, and four publications. Preliminary results from a phase 2 study of Dacogen in elderly patients with acute myeloid leukemia (AML) and a retrospective survival analysis of Dacogen-treated patients with chronic myelomoncytic leukemia (CMML) were among the data presented. In addition, MGI PHARMA sponsored a corporate symposium on Friday, December 8 titled The Therapeutic Potential of Epigenetics in MDS and AML, which was chaired by Dr. Jean-Pierre Issa of The University of Texas M.D. Anderson Cancer Center in Houston, Texas.
